Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

NCT02367859 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Ameloblastoma
BRAF Gene Mutation

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Stanford University

Collaborators

[object Object]